Search by PDG name  
   

 

FGFR3  
    


    
      Official symbol:  FGFR3
      Full name:  fibroblast growth factor receptor 3
      Location:  4p16.3
      Also known as:  CEK2, JTK4, CD333, ACH
      Entrez ID:  2261
      Ensembl ID:  ENSG00000068078
      Summary:  This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in this gene lead to craniosynostosis and multiple types of skeletal dysplasia. [provided by RefSeq, Aug 2017]

    

    
  Overall distribution
    
  Tissue specific distribution
    
 
  
 
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Gscore (Amp):  1.56  (Driver)
Gscore (Del):  0.00  
 
Recurrently amplified in 3 cancer type(s)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Mscore:  0.63  (Driver)
 
Recurrently mutated in 3 cancer type(s)
   

    
  Overall
    
  Tissue specific
    
 
Total fusion occurrence:  40  (Driver)
 
Fusions detected in 11 cancer type(s)
 
 

    
  Overall
    
  Tissue specific
    
   CRISPR: STRONGLY SELECTIVE 
 RNAi: STRONGLY SELECTIVE 
   
   

    
      Functional class:  Kinase (protein kinase)
      JensenLab PubMed score:  1050.14  (Percentile rank: 95.56%)
      PubTator score:  1032.93  (Percentile rank: 96.66%)
      Target development/druggability level:  TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action.
      Tractability (small molecule):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
      Tractability (antibody):  Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted

    







Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.